-  INCLUSION CRITERIA:

        Adult patients with documented deleterious breast cancer 1 and breast cancer 2 (BRCA 1 or
        2) mutations with histologically confirmed ovarian, primary peritoneal, breast, prostate,
        pancreas, gastric or other solid tumor whose disease has progressed following at least one
        standard therapy or who have no acceptable standard treatment options.

        Patients with ovarian cancer should have one prior platinum-based

        chemotherapeutic regimen for management of primary disease containing carboplatin,
        cisplatin, or another organoplatinum compound. This initial treatment may have included
        intraperitoneal therapy, consolidation, biologic/targeted (noncytotoxic) agents or extended
        therapy administered after surgical or non-surgical

        assessment. Ovarian cancer patients with both platinum-sensitive and platinum resistant
        disease are eligible. Patients with platinum-refractory disease are NOT eligible.

        Patients with metastatic disease must have received at least one line of standard of care
        (SOC) treatment for metastatic disease prior to enrollment

          -  Age greater than or equal to 18 years of age.

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2

          -  Life expectancy of greater than 3 months.

          -  Patients must have normal organ and marrow function as defined below:

               -  leukocytes greater than or equal to 3,000/mcL

               -  absolute neutrophil count greater than or equal to 1,500/mcL

               -  platelets greater than or equal to 100,000/mcL

               -  total bilirubin less than or equal to 1.5 times institutional upper limit of
                  normal

               -  Aspartate aminotransferase (AST) Serum glutamic-oxaloacetic transaminase
                  (SGOT)/alanine aminotransferase (ALT) Serum glutamic pyruvic transaminase (SGPT)
                  less than or equal to 3 times institutional upper limit of normal

               -  creatinine less than or equal to 1.5 times institutional upper limit of normal

        OR

        --creatinine clearance greater than or equal to 60 mL/min for patients with creatinine
        levels above institutional normal.

        The effects of BMN 673 on the developing human fetus are unknown. For this reason and
        because PARP inhibitors are known to be teratogenic, women of childbearing potential and
        men must agree to use adequate contraception (hormonal or barrier method of birth control;
        abstinence) prior to study entry, for the duration of study participation, and for 30 days
        after completing study treatment. Should a woman become pregnant or suspect she is pregnant
        while she or her partner is participating in this study, she should inform her treating
        physician immediately. Men treated or enrolled on this protocol must also agree to use
        adequate contraception prior to the study, for the duration of study participation, and for
        3 months after completion of BMN 673 administration.

          -  Patients must be able to swallow whole tablets or capsules. Nasogastric or G-tube
             administration is not allowed. Any gastrointestinal disease which would impair ability
             to swallow, retain, or absorb drug is not allowed.

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast
             cancer or ovarian cancer should have received at least two lines of systemic therapy
             in the advanced setting.

          -  Patients with prostate cancer can continue to receive treatment with
             Gonadotropin-releasing hormone (GnRH) agonists while on study, as long as there is
             evidence of disease progression on therapy.

        EXCLUSION CRITERIA:

          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entering the study or those who have not
             recovered from adverse events due to agents administered more than 4 weeks earlier.
             Patients who have had prior treatment with any PARP inhibitors are ineligible.

          -  Patients who are receiving any other investigational agents.

          -  Patients with known active brain metastases or carcinomatous meningitis are excluded
             from this clinical trial. Patients whose brain metastatic disease status has remained
             stable for greater than or equal to 4 weeks following treatment of brain metastases
             are eligible to participate at the discretion of the principal investigator.

          -  Eligibility of subjects receiving any medications or substances with the potential to
             affect the activity or pharmacokinetics of BMN 673 will be determined following review
             by the principal investigator.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant women are excluded from this study because the effects of the study drugs on
             the developing fetus are unknown.

          -  human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible because of the potential for pharmacokinetic interactions with
             BMN 673. In addition, these patients are at increased risk of lethal infections when
             treated with marrow suppressive therapy. Appropriate studies will be undertaken in
             patients receiving combination antiretroviral therapy when indicated.

          -  Patients who require use of coumarin-derivative anticoagulants such as warfarin are
             excluded. Low molecular weight heparin is permitted for prophylactic or therapeutic
             use. Low-dose warfarin (less than or equal to 1 mg/day) is permitted.

          -  Women who are currently lactating